Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Studies found that AstraZeneca’s EVUSHELD was still effective against the Omicron variant. EVUSHELD is a long-acting antibody combination made up of tixagevimab and cilgavimab.
Janssen Pharmaceutical says goodbye to San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.
The latest approvals mark the first time a biologic has been approved for ERA. Cosentyx is also the only biologic approved in the United States for both ERA and PsA in pediatric patients.
New real-world studies from Scotland and England shows that Omicron does not lead to as much hospitalization as Delta. This is consistent with the latest reports from South Africa that say Omicron causes milder disease.
The FDA has approved Novartis’ new drug for lowering bad cholesterol. Leqvio is the first and only siRNA treatment that can reduce low-density lipoprotein cholesterol.
PhaseBio’s move to suspend its Phase IIb trial of pemziviptadil is due to the effect of COVID-19 on manufacturing, associated drug supply, and the rate of enrollment in the study.
The U.S. Food and Drug Administration granted Emergency Use Authorization to Pfizer’s Paxlovid (nirmatrelvir and ritonavir tablets) for high-risk adults and pediatric patients 12 years and older to treat COVID-19.
With all eyes on a new year, life sciences companies and organizations are making last-minute appointments to strengthen their leadership teams and board with these Movers & Shakers.
Takeda hoped that its experimental therapy could become the first FDA-approved treatment for EoE. However, the FDA wants the company to initiate another clinical study with TAK-721.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The company aims to use the $100 million investment to support biotechnology firms involved in treating mental diseases and longevity projects.
Aduhelm was approved by the U.S. FDA for its ability to clear beta-amyloid. Researchers at Emory investigated the use of an FDA-approved ADHD medication on patients with mild Alzheimer’s symptoms and found it appeared to reduce levels of tau.